Industries has been added to Bookmarks.
Navigating what’s next
On March 27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) into law. What are important considerations for life sciences and health care companies? Participants will gain insight on provisions of the CARES Act and explore ways it can assist in the financial response to the COVID-19 pandemic.
In the face of unprecedented disruptions, manufacturers are undergoing transformation from analog to digital processes and products. Understanding key shifts and identifying strategies to navigate them could enable manufacturers to thrive in the next decade. Participants will discover how five key trends could affect manufacturing this decade and explore several approaches that can both mitigate their impact and position manufacturers for success.
Cell, gene, and other emerging therapies are distinctly different from traditional biopharma products. Despite clinical and commercial promise, as with any new and innovative disruptive technology, cell and gene therapy stakeholders face challenges across the product life cycle. Participants will gain insights on emerging precision medicines and examine various approaches to bringing them to market.
Many government agencies have started on their artificial intelligence (AI) journey. However, some may not have developed a holistic strategy to guide them. Participants will discover the role of strategy in optimizing their AI programs and explore ways to achieve the maximum potential for the mission, the workforce, and citizens of today and tomorrow.
As life sciences and health care companies navigate toward the future of health, new technology capabilities are likely to be required. Many organizations have set up venture arms to assess new possibilities for investment and potential growth opportunities. Participants will consider new archetypes that organizations will rearrange themselves around and explore ways they might position themselves for success in the future of health.
An estimated $4 trillion gap exists between what should be spent on US infrastructure and what actually is being spent. This means that government agencies are planning, budgeting, and operating thousands of infrastructure assets without enough routine maintenance or major recapitalization. Participants will explore the magnitude of the deferred maintenance issue and discover tools and techniques for managing and even overcoming potential crises.
As artificial intelligence (AI) becomes more widespread, adopters of AI technologies are increasingly worried about its emerging risks and application trustworthiness. How are technology, media, and telecommunications (TMT) companies using and creating AI and confronting the risks? Participants will gain new insights on these and other issues and explore how TMT companies are transforming with AI technologies.
Energy, Resources, & Industrials
Government & Education
Industrial Products & Construction
Life Sciences & Health Care
Oil, Gas, & Chemicals
Power, Utilities, & Renewables
Retail, Wholesale, & Distribution
Technology, Media, & Telecommunications
Transportation, Hospitality, & Services